Immune Signatures in Patients with Psoriasis Vulgaris of Blood‐Heat Syndrome: A Systematic Review and Meta‐Analysis

Abstract

Objective. To determine whether immunological serum markers IFN-γ, IL-4, IL-17, IL-23, IL-6, TNF-α, and IL-10 are elevated or decreased in patients compared with healthy controls. Methods. A complete search of the literature on this topic within the past 30 years was conducted across seven databases. Seventeen studies including 768 individuals were identified. Differences in serum marker levels between subjects and controls were pooled as MDs using the random-effects model. Results. The pooled MDs were higher in patients than in healthy controls for IFN-γ (MD 24.9, 95% CI 12.36–37.43), IL-17 (MD 28.92, 95% CI 17.44–40.40), IL-23 (MD 310.60, 95% CI 4.96–616.24), and TNF-α (MD 19.84, 95% CI 13.80–25.87). Pooled IL-4 (MD −13.5, 95% CI −17.74–−9.26) and IL-10 (MD −10.33, 95% CI −12.03–−8.63) levels were lower in patients. Conclusion. The pooled analyses suggest that levels of IFN-γ, IL-17, IL-23, and TNF-α are significantly elevated and that levels of IL-4 and IL-10 are significantly decreased in sera of patients with psoriasis vulgaris of blood-heat syndrome. Measuring progression of blood-heat syndrome of psoriasis vulgaris will require additional high-quality data, with a low risk of bias and adequate sample sizes, before and after antipsoriatic therapy.

Our Choice: study protocol for a randomized controlled trial for optimal implementation of psoriasis treatment by the integration of Chinese and Western Medicine

“…We therefore considered JYG as a safe and effective medication for the treatment of psoriasis. Results from a pooled analysis conducted by us also indicated that levels of IFN-γ, IL-17, IL-23, and TNF-α were significantly increased, whereas those of IL-4 and IL-10 were significantly decreased in the sera of patients with blood-heat syndrome of psoriasis [43]. Determining the effect of the JY prescription on the aforementioned immune factors will be a focus area of our future research.…”

Our Choice: study protocol for a randomized controlled trial for optimal implementation of psoriasis treatment by the integration of Chinese and western medicine

“…We therefore considered JYG as a safe and effective medication for the treatment of psoriasis. Results from a pooled analysis conducted by us also indicated that levels of interferon-γ, IL-17, IL-23, and tumor necrosis factor-α were significantly increased, whereas those of IL-4 and IL-10 were significantly decreased in the sera of patients with blood-heat syndrome of psoriasis [42]. Determining the effect of the JY prescription on the aforementioned immune factors will be a focus area of our future research.…”

TNF stimulates IL‐6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin

“…The prevalence of psoriasis in the United States is about 3% [115] and is considered a major public health problem due to ineffective long-term treatments that resulted in an estimated economic burden amounting to $11 billion in 2013. [116,117] Recent studies on the pathogenesis of psoriasis have revealed not only a genetic component, [118] but also immune dysfunction, [119] as evidenced by an imbalance in resident and infiltrating skin immune cells, including dendritic cells, macrophages [41] and MC. [3,14,19,91,120] Our findings reveal that TNF stimulates KC proinflammatory mediator secretion via mTOR activation.…”